Carter HB - Search Results

1

The biology of prostate cancer: new and future directions in predicting tumor behavior.

Partin AW, Carter HB, Epstein JI, Coffey DS. Partin AW, et al. Among authors: carter hb. Monogr Pathol. 1992;(34):198-218. Monogr Pathol. 1992. PMID: 1406742 Review.

2

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Partin AW, et al. Among authors: carter hb. J Urol. 1990 Apr;143(4):747-52. doi: 10.1016/s0022-5347(17)40079-6. J Urol. 1990. PMID: 1690309 Free article.

3

The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.

Carter HB, Partin AW, Epstein JI, Chan DW, Walsh PC. Carter HB, et al. J Urol. 1990 Nov;144(5):1167-70; discussion 1170-1. doi: 10.1016/s0022-5347(17)39683-0. J Urol. 1990. PMID: 1700143

4

Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge.

Carter HB, Partin AW, Coffey DS. Carter HB, et al. J Urol. 1989 Nov;142(5):1338-41. doi: 10.1016/s0022-5347(17)39093-6. J Urol. 1989. PMID: 2810530

5

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Partin AW, et al. Among authors: carter hb. Urology. 1994 May;43(5):649-59. doi: 10.1016/0090-4295(94)90180-5. Urology. 1994. PMID: 7513108

6

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. Partin AW, et al. Among authors: carter hb. J Urol. 1993 Jul;150(1):110-4. doi: 10.1016/s0022-5347(17)35410-1. J Urol. 1993. PMID: 7685418 Free article.

7

Relationship between changes in prostate-specific antigen and prognosis of prostate cancer.

Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter HB. Cadeddu JA, et al. Among authors: carter hb. Urology. 1993 Oct;42(4):383-9. doi: 10.1016/0090-4295(93)90362-e. Urology. 1993. PMID: 7692658 Free article.

8

The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.

Pannek J, Subong EN, Jones KA, Marschke PL, Epstein JI, Chan DW, Carter HB, Luderer AA, Partin AW. Pannek J, et al. Among authors: carter hb. Urology. 1996 Dec;48(6A Suppl):51-4. doi: 10.1016/s0090-4295(96)00610-3. Urology. 1996. PMID: 8973700 Free article. Clinical Trial.

9

Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate.

Carter HB, Epstein JI. Carter HB, et al. World J Urol. 1997;15(6):359-63. doi: 10.1007/BF01300183. World J Urol. 1997. PMID: 9436285 Review.

10

Expectant management of localized prostate cancer.

Khan MA, Partin AW, Carter HB. Khan MA, et al. Among authors: carter hb. Urology. 2003 Nov;62(5):793-9. doi: 10.1016/s0090-4295(03)00653-8. Urology. 2003. PMID: 14624896 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters